

1. Record Nr.	UNINA9910808949303321
Titolo	Bayesian adaptive methods for clinical trials // Scott M. Berry ... [et al.]
Pubbl/distr/stampa	Boca Raton, : Chapman & Hall/CRC, 2010
ISBN	0-429-15242-6 1-282-90299-7 9786612902994 1-4398-2551-3
Edizione	[1st ed.]
Descrizione fisica	1 online resource (316 p.)
Collana	Chapman & Hall/CRC biostatistics series ; ; 38
Altri autori (Persone)	BerryScott M
Disciplina	615.5072/4
Soggetti	Clinical trials - Statistical methods Bayesian statistical decision theory
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and indexes.
Nota di contenuto	Front cover; Contents; Foreword; Preface; CHAPTER 1: Statistical approaches for clinical trials; CHAPTER 2: Basics of Bayesian inference; CHAPTER 3: Phase I studies; CHAPTER 4: Phase II studies; CHAPTER 5: Phase III studies; CHAPTER 6: Special topics; References; Back cover
Sommario/riassunto	As has been well-discussed, the explosion of interest in Bayesian methods over the last 10 to 20 years has been the result of the convergence of modern computing power and efficient Markov chain Monte Carlo (MCMC) algorithms for sampling from and summarizing posterior distributions. Practitioners trained in traditional, frequentist statistical methods appear to have been drawn to Bayesian approaches for three reasons. One is that Bayesian approaches implemented with the majority of their informative content coming from the current data, and not any external prior information, typically have good frequentist properties (e.g., low mean squared error in repeated use). Second, these methods as now readily implemented in WinBUGS and other MCMC-driven software packages now over the simplest approach to hierarchical (random effects) modeling, as routinely needed in longitudinal, frailty, spatial, time series, and a wide variety of other settings featuring interdependent data. Third, practitioners are attracted by the greater flexibility and adaptivity of the Bayesian

approach, which permits stopping for efficacy, toxicity, and futility, as well as facilitates a straightforward solution to a great many other specialized problems such as dose-finding, adaptive randomization, equivalence testing, and others we shall describe. This book presents the Bayesian adaptive approach to the design and analysis of clinical trials--Provided by publisher.
